Author/Authors :
Nardone, V Unit of Radiation Oncology - Ospedale del Mare, Naples, Italy , Reginelli, A Department of Precision Medicine - University of Campania “L. Vanvitelli”, Naples, Italy , Vitale, C Department of Precision Medicine - University of Campania “L. Vanvitelli”, Naples, Italy , Calvanese, M.G Unit of Radiation Oncology - Ospedale del Mare, Naples, Italy , Correale, P Unit of Medical Oncology - Grand Metropolitan Hospital “Bianchi Melacrino Morelli”, Reggio Calabria, Italy , Grassi, R Department of Precision Medicine - University of Campania “L. Vanvitelli”, Naples, Italy , Falivene, S Unit of Radiation Oncology - Ospedale del Mare, Naples, Italy , Sangiovanni, A Department of Precision Medicine - University of Campania “L. Vanvitelli”, Naples, Italy , Cappabianca, S Department of Precision Medicine - University of Campania “L. Vanvitelli”, Naples, Italy , Guida, C Unit of Radiation Oncology - Ospedale del Mare, Naples, Italy
Abstract :
Background: We report a case of a metastatic breast cancer woman undergoing therapy with fulvestrant and palbociclib that was successfully
treated with thoracic stereotactic ablative radiation therapy (SABR) for a hilar
lymph node metastasis. Case Description: The patient began the radiation
treatment in the week off of the palbociclib and reported no acute toxicity.
The CT scan showed acute pneumonia 60 days after RT although the patient
reported no symptomatology. In addition, the subsequent PET/TC scan
performed six months after RT exhibited a complete response of the
irradiated lesion. Conclusion: The use of SABR in patients undergoing cyclin
inhibitors appears to be potentially effective although the association must be further studied to investigate the toxicities.
Keywords :
Cycline inhibitors , breast cancer , SABR , stereotactic radiation therapy , reirradiation
